ETAP: Endovascular treatment of atherosclerotic popliteal artery lesions: a prospective, multi-center, randomized study.

Introduction: The popliteal artery is a vessel considered unfavorable for the implantation of a stent due to the forces exerted in the popliteal fossa during limb flexion, which could fracture the stent antlers and compromise the outcome of the procedure at long-term. So far, stents used in popliteal lesions have not been compared with balloon angioplasty. The ETAP study is the first study in humans or FIM (first in man) comparing stenting with nitinol, (LifeStent ®), versus balloon angioplasty.

Methods and Results: 246 patients were included in nine European centers, being randomized 1:1. The primary object was restenosis rate at one year. Secondary objectives were restenosis at 6, 12 and 24 months, primary artery permeability as well as reintervention of target lesion. The medium length of lesions was 44 mm, with 33% of occlusions. After 12 months, the artery permeability observed was 44.9% in the angioplasty group versus 67.4% stent implantation (p <0.05). There was a lower rate of reoperation at 12 months with stent implantation (15.4 versus 50.4%, p = 0.0001). The stent fracture rate at one year was 3.4%.

Conclusion: Stent fracture on popliteal injury is not a common occurrence with the use of nitinol modern stents and does not invalidate the use of stents for such injuries. Stent implantation was superior to conventional angioplasty for the treatment of popliteal lesions. Future studies should examine the role of stenting in this era of drug-eluting balloon angioplasty.

4_thomas_zeller
Thomas Zeller
2012-10-24

Original title: Endovascular Treatment of Atherosclerotic Popliteal Artery Lesions – Balloon Angioplasty versus primary Stenting: A prospective, multi-centre, randomised study ETAP

More articles by this author

MASTER Trial: Prospective, multicentre, randomized trial evaluating the MGuard stent in the treatment of patients with acute myocardial infarction with ST segment elevation (STEMI).

Foreword: The EPS MGUARD stent (embolic protection stent) has a fine metal structure covered by a thin polyethylene fiber mesh with pores of 5...

PARTNER cohort B: Clinical events at 3 years follow-up in patients with

Background: Percutaneous aortic valve implantation (TAVI) is the treatment of choice for patients with severe aortic stenosis considered inoperable according to clinical outcomes at...

ISAR-LEFT MAIN 2: Everolimus-eluting stents versus Zotarolimus eluting stents in the treatment of the unprotected left coronary trunk.

Summary: Second-generation drug-eluting stents have shown better results than their predecessors. In this study we compare two second-generation drug stents in patients with unprotected...

FAME 2: Cost-effectiveness of FFR-guided angioplasty in patients with stable angina

Introduction: FAME study 2, presented at the European Congress of Cardiology 2012, is a multicenter study that randomized patients with stable angina FFR-guided angioplasty...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2026 | ALL-RISE Trial: Coronary Physiological Assessment Using FFRangio

Coronary physiological assessment using pressure-wire techniques (FFR/iFR) carries a Class IA recommendation in ACC/AHA guidelines; however, its use remains limited due to factors such...

ACC 2026 | Protect The Head-To-Head Trial: Randomized Comparison Between Emboliner and Sentinel During TAVI

Ischemic stroke remains one of the most feared complications of TAVI, with a relatively low but persistent incidence of 2–4%, without significant reduction over...

ACC 2026 | PRO-TAVI Trial: Deferring Coronary Angioplasty in Patients Undergoing TAVI

Coronary artery disease is common in patients with severe aortic stenosis undergoing TAVI. Current guidelines recommend considering revascularization in significant coronary lesions, particularly in...